TVM Capital, MSD and Dr. Ali Ertürk talk about the VC-market, pharmaceutical cooperations and new technologies

“We are pleased that industry leaders and high-profile scientists are presenting strategies of the venture capital and pharmaceutical business, or pioneering research results at the Biotech Press Lounge, and that multipliers are regularly using the event to network,” said Dr. Peter Hanns Zobel, Managing Director of the IZB, at the beginning of the 10th Biotech Press Lounge on February 21, 2019.

Dr. Ing. Hubert Birner, Managing Partner of TVM Capital GmbH and Phil L’Huillier, Ph.D., Head of Business Development Europe & Middle East MSD Innovation Hub, gave interesting keynote speeches before the 100 guests. Dr. Ali Ertürk, at that time a group leader at the Institue for Stroke and Dementia Research of the University Munich (now Helmholtz Center), presented a technology to produce 3D bio-printed organs within five years.

The journalist Eva Müller from Manager Magazine moderated the event with 100 guests from biotech, pharmaceutical and venture capital companies as well as top researchers from the Martinsried Campus in the Faculty Club G2B (Gateway to Biotech). She first announced Dr. Hubert Birner, a veteran of the venture capital scene. In his presentation titled “Sleepless Nights in 2019 for a Venture Capitalist,” he first illuminated the financing business in 2018 in German-speaking countries, highlighted the fundraising environment for biotech companies and investors, and looked at possible deals in 2019. Phil L’Huillier, Ph.D., talked about “Collaboration Opportunities with MSD and the New Discovery Research Center in London”. In his keynote address, “Transformative Technologies to Accelerate Biomedical Research and Treat Fatal Diseases in Our Lives,” Dr. Ali Ertürk presented his new imaging technologies, a combination of artificial intelligence, nanotechnology, and Engineering.